Search
Close this search box.

Moderna’s Combination Vaccine for COVID and Flu, Offers Better Protection: Study

Moderna

Clinical trials show that a combined flu and COVID-19 vaccine may elicit a higher immune response compared to separate inoculations. Moderna, the biotech firm behind the Spikevax vaccine used in NHS booster programs, is trialling a two-in-one jab that offers protection against both flu and COVID-19. Initial results indicate this combined vaccine may provide better protection than the current separate vaccines.

The trial results demonstrated that participants who received the combined vaccine had higher antibody responses against both flu and COVID-19 compared to those who received the vaccines separately. Moderna hopes to make this vaccine widely available as early as next year.

The findings are based on a randomized controlled phase 3 trial involving 8,000 participants divided into two groups. The first group, aged 65 and over, tested the new combined jab against the flu vaccine and the Spikevax jab. The second group consisted of adults aged 50 to 64.

Stéphane Bancel, Moderna’s CEO, stated, “Combination vaccines have the potential to reduce the burden of respiratory viruses on health systems and pharmacies, as well as offer people more convenient vaccination options that could improve compliance and provide stronger protection from seasonal illnesses.” He added, “Moderna is the only company with a positive phase 3 flu and COVID combination vaccine. Building on the momentum of positive phase 3 data across our respiratory portfolio, we continue to address significant unmet medical needs and advance public health.”

Earlier this year, Boots announced that it would offer the Pfizer-BioNTech vaccine to healthy customers in England aged 12 and over, priced at £98.95 per jab.

Read More: Click Here

Share:

Facebook
Twitter
WhatsApp
LinkedIn

Copyright 2023 © Insightscare Magazine ( a Digital Ink brand ) All rights reserved.